Clinical trial Recruiting at 1 site Interventional Ages 14 to 70

Blocking blood flow during pancreatic tumor removal

Official title: A Prospective Study of Enucleation of Pancreatic Tumor by Blocking Abdominal Trunk and Superior Mesenteric Artery

Run by Zhejiang University · NCT06164769 · Data updated 2026-11-12

This study is testing a new way to remove certain pancreatic tumors while reducing bleeding and protecting healthy tissue in patients with benign or borderline tumors.

Quick facts

Study typeInterventional
Ages14 Years to 70 Years
SexAll
Enrollment30 (estimated)
SponsorZhejiang University
Academic / other
Locations1 site (Hangzhou, Zhejiang)
StatusRecruiting
StartedMarch 1, 2023
Main results expectedMay 30, 2026
Study endsJune 30, 2026
Registry record updatedJune 2, 2025
Trial IDNCT06164769 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients with benign or borderline pancreatic tumors located in the head, neck, or uncinate process of the pancreas.

Probably not a fit

Patients with highly malignant tumors or those located in the body and tail of the pancreas will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates a novel technique for laparoscopic enucleation of pancreatic tumors by blocking the abdominal trunk and superior mesenteric artery to minimize intraoperative bleeding. The approach aims to preserve healthy pancreatic tissue and reduce the risk of tumor recurrence. Conducted at the Second Affiliated Hospital of Zhejiang University, the study will include patients with benign or borderline pancreatic tumors located in the head, neck, or uncinate process of the pancreas. Data on clinical, biochemical, and radiological characteristics will be collected and analyzed throughout the study period from March 2023 to May 2026.

Why it matters

Potential benefit: If successful, this method could lead to safer surgical procedures with less blood loss and better preservation of pancreatic function.

How similar studies have gone: While this approach is innovative, similar studies have shown promise in reducing surgical complications associated with pancreatic surgeries.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Benign or borderline tumors diagnosed pathologically, such as pancreatic neuroendocrine tumors, solid pseudopapillary tumors, and cystadenomas, without vascular invasion or distant metastasis
* Tumors sited in the pancreatic head, neck, and uncinate process of pancreas
* Blockade of both the abdominal trunk and superior mesenteric artery in the laparoscopic enucleation

Exclusion Criteria:

* Highly malignant pancreatic tumors, or tumors with infiltration or metastasis
* Tumors of the body and tail of the pancreas
* Transfer to LPD or laparotomy

Where it's running

  • the Second Affiliated Hospital of Zhejiang University
    Hangzhou, Zhejiang, China
    Recruiting

Study contacts

  • Principal investigator: Bo Zhou, Dr. — The Second Affiliated Hospital, Zhejiang Chinese Medical University
  • Study coordinator: Sheng Yan, professor
  • Email: shengyan@zju.edu.cn
  • Phone: +86-13957161680

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.